Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2017

01-08-2017 | Clinical trial

A prospective randomized controlled trial of hydrating nail solution for prevention or treatment of onycholysis in breast cancer patients who received neoadjuvant/adjuvant docetaxel chemotherapy

Authors: Ji-Yeon Kim, Oh Nam Ok, Jeong-ju Seo, Soo-Hyeon Lee, Jin Seok Ahn, Young-Hyuck Im, Yeon Hee Park

Published in: Breast Cancer Research and Treatment | Issue 3/2017

Login to get access

Abstract

Purpose

Onycholysis and other nail toxicities occur in approximately 20–30% of breast cancer (BC) patients receiving docetaxel chemotherapy. Onycholysis is often associated with painful paronychia, decreasing patients’ quality of life. In this study, we aimed to evaluate the efficacy of hydrating nail solution (HNS) (EVONAIL® solution, Evaux Laboratories, France) for the prevention and treatment of docetaxel-induced onycholysis and nail toxicities.

Methods

This study was a prospective, randomized, controlled study of HNS for the prevention or treatment of onycholysis in patients with docetaxel after doxorubicin plus cyclophosphamide. In the experimental arm, patients painted HNS on nails and periungual areas once a day till developing onycholysis grade 2. After grade 2 onycholysis development, patients applied HNS twice a day regardless of treatment arm. The primary endpoints were the incidence of onycholysis grade 2 and recovery rate from grade 2 onycholysis.

Results

From August 2015 to May 2016, 103 patients were enrolled and completed this study. Of these, 25 cases of grade 1 and 22 of grade 2 onycholysis were observed. Prophylactic application of HNS resulted in a statistically significant reduction of grade 2 onycholysis compared to controls (P = 0.001) and all grade onycholysis was also significantly lower in the experimental arm (P = 0.034). Multivariate analysis showed that HNS decreased grade 2 onycholysis (Hazard ratio (HR) 0.366, 95% confidence interval (CI) 0.148, 0.902; P = 0.029) and all grade onycholysis (HR 0.372, 95% CI 0.201–0.687, P = 0.002).

Conclusions

Hydrating nail solution significantly reduced the incidence of docetaxel-induced onycholysis in BC patients (NCT02670603).
Appendix
Available only for authorised users
Literature
1.
2.
3.
4.
5.
Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, Tomiak E, Al-Tweigeri T, Chap L, Juhos E, Guevin R, Howell A, Fornander T, Hainsworth J, Coleman R, Vinholes J, Modiano M, Pinter T, Tang SC, Colwell B, Prady C, Provencher L, Walde D, Rodriguez-Lescure A, Hugh J, Loret C, Rupin M, Blitz S, Jacobs P, Murawsky M, Riva A, Vogel C, Breast Cancer International Research Group I (2005) Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352:2302–2313. doi:10.​1056/​NEJMoa043681 CrossRefPubMed
6.
Martin M, Segui MA, Anton A, Ruiz A, Ramos M, Adrover E, Aranda I, Rodriguez-Lescure A, Grosse R, Calvo L, Barnadas A, Isla D, Martinez del Prado P, Ruiz Borrego M, Zaluski J, Arcusa A, Munoz M, Lopez Vega JM, Mel JR, Munarriz B, Llorca C, Jara C, Alba E, Florian J, Li J, Lopez Garcia-Asenjo JA, Saez A, Rios MJ, Almenar S, Peiro G, Lluch A, Investigators G (2010) Adjuvant docetaxel for high-risk, node-negative breast cancer. N Engl J Med 363:2200–2210. doi:10.​1056/​NEJMoa0910320 CrossRefPubMed
7.
8.
Minisini AM, Tosti A, Sobrero AF, Mansutti M, Piraccini BM, Sacco C, Puglisi F (2003) Taxane-induced nail changes: incidence, clinical presentation and outcome. Ann Oncol 14:333–337CrossRefPubMed
9.
Roche H, Fumoleau P, Spielmann M, Canon JL, Delozier T, Serin D, Symann M, Kerbrat P, Soulie P, Eichler F, Viens P, Monnier A, Vindevoghel A, Campone M, Goudier MJ, Bonneterre J, Ferrero JM, Martin AL, Geneve J, Asselain B (2006) Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol 24:5664–5671. doi:10.​1200/​JCO.​2006.​07.​3916 CrossRefPubMed
10.
11.
Scotte F, Tourani JM, Banu E, Peyromaure M, Levy E, Marsan S, Magherini E, Fabre-Guillevin E, Andrieu JM, Oudard S (2005) Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. J Clin Oncol 23:4424–4429. doi:10.​1200/​JCO.​2005.​15.​651 CrossRefPubMed
12.
Fabbro CM, Del Cont L, Polesel J, Tabaro G (2016) Efficacy of cryotherapy in paclitaxel-induced nail toxicity: preliminary results from a Phase II clinical study. Ann Oncol 27(Supplement 4):iv80–iv84. doi:10.​1093/​annonc/​mdw339.​2 CrossRef
13.
Capriotti K, Capriotti JA, Lessin S, Wu S, Goldfarb S, Belum VR, Lacouture ME (2015) The risk of nail changes with taxane chemotherapy: a systematic review of the literature and meta-analysis. Br J Dermatol 173:842–845. doi:10.​1111/​bjd.​13743 CrossRefPubMed
14.
Scotte F, Banu E, Medioni J, Levy E, Ebenezer C, Marsan S, Banu A, Tourani JM, Andrieu JM, Oudard S (2008) Matched case-control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot. Cancer 112:1625–1631. doi:10.​1002/​cncr.​23333 CrossRefPubMed
15.
Chanez J-F (2010) The neurogenic component of cutaneous toxicities induced by chemotherapy—new solutions. Euro Oncol 6(1):28–30
Metadata
Title
A prospective randomized controlled trial of hydrating nail solution for prevention or treatment of onycholysis in breast cancer patients who received neoadjuvant/adjuvant docetaxel chemotherapy
Authors
Ji-Yeon Kim
Oh Nam Ok
Jeong-ju Seo
Soo-Hyeon Lee
Jin Seok Ahn
Young-Hyuck Im
Yeon Hee Park
Publication date
01-08-2017
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2017
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-017-4268-7

Other articles of this Issue 3/2017

Breast Cancer Research and Treatment 3/2017 Go to the issue

Preclinical study

Impact of serum HER2, TIMP-1, and CAIX on outcome for HER2+ metastatic breast cancer patients: CCTG MA.31 (lapatinib vs. trastuzumab)

Review

Critical appraisal of health-state utility values used in breast cancer-related cost–utility analyses

Clinical trial

High expression of cyclin D1 is associated to high proliferation rate and increased risk of mortality in women with ER-positive but not in ER-negative breast cancers

Preclinical study

Contribution of germline mutations in cancer predisposition genes to tumor etiology in young women diagnosed with invasive breast cancer

Erratum

Erratum to: Breast cancer risk models: a comprehensive overview of existing models, validation, and clinical applications

Erratum

Erratum to: Comparative clinical utility of tumor genomic testing and cell-free DNA in metastatic breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits